Cancer Prevention and Research Institute of Texas
Gulf Coast Consortia
Combinatorial Drug Discovery Program

Screening Application

Principal Investigator:

Position:

Institution:

Address:

Phone#

Email:

Submit by:

Project Title (*max 200 chars*):

Please explain funding arrangements

I am seeking support from the HTS pro bono fund:	Yes
Do you have a dead line which data is expected from the screen?	Yes
If yes, what will be the dead line?	03/01/2024

Describe the goals of this project (*max 2000 chars)*:

How will this project impact your research (*max 2000 chars*):

Brief description of your current assay method (including assay format, end point, positive/negative, controls..etc)

Assay References (include any relevance publications related to your project with pubmed ID)

Select one or more compound collections for these studies by checking the appropriate boxes. Visit our website for description of each library.

- [ ] CCI_2022
- [ ] Custom Clinical_2021
- [ ] NCI_AODX
- [ ] Selleck Bioactive
- [ ] Prestwick_V2
- [ ] Selleck_GPCR LOPAC
- [ ] Broad_2021
- [ ] Microsource
- [ ] UTKINASE_V5
- [ ] NIH CustomClinical
- [ ] NCI_V2
- [ ] CTEP_2022
- [ ] Investigator's own collections
- [ ] MCE_Epigenetics
- [ ] SGC_Epigenetics
- [ ] MCE_FDA
- [ ] TargetMol_Approved Drug
- [ ] TargetMol_Epigenetics
- [ ] TargetMol_PI3K-AKT-mTOR
- [ ] TargetMol_MAPK Inhibitor
- [ ] TargetMol_Tyrosine kinase inhibitor
- [ ] TargetMol_Ion Channel Inhibitor
- [ ] TargetMol_Endocrinology-Hormones
- [ ] TargetMol_Neuronal Signaling
- [ ] TargetMol_Oxidation-Reduction
- [ ] TargetMol_Mitochondrial Targeting
- [ ] TargetMol_Autophagy
- [ ] TargetMol_Cell cycle related
- [ ] TargetMol_Apoptosis
- [ ] TargetMol_JAK STAT
- [ ] TargetMol_Wnt_Hedgehog_Notch
- [ ] TargetMol_DNA Damage Repair
- [ ] TargetMol_Fluorochemical
- [ ] TargetMol_Anti-Metabolism disease
- [ ] TargetMol_Natural Product
- [ ] TargetMol_Stem Cell
- [ ] TargetMol_Bioactive

Disclaimer

We would like to inform you that in addition to testing the commercially sourced collections of drugs above in the cell-based models you provide, we will also be testing our own proprietary compounds at no cost to you. If you prefer that your cell-based models not be used for testing our proprietary compounds, please notify us to opt out of this specific testing. It is possible that testing these agents in your model could lead to new and exciting follow-up contacts with other investigators. It is our intention that this opportunity to test new and unique agents may foster further collaborations among investigators.